Print

Find A Doctor

The UCLA Memory Disorders Clinic is a component of Mary S. Easton Center for Alzheimer's Disease Research at UCLA (UCLA - Easton Center) specializes in the evaluation and diagnosis of Mild Cognitive Impairment, early Alzheimer's disease (AD), frontotemporal dementia (FTD), and related disorders. An early diagnosis enables patients to take advantage of the most effective therapies and to maintain the highest level of functioning for the longest period of time. Callers can speak directly with the triage coordinator who will collect relevant medical information, and with input from expert clinicians, schedule patients or refer to the most appropriate UCLA clinic. Please contact Doug Hawkins at (310) 794-6039.

UCLA Alzheimer's Disease Research Center clinic appointment UCLA Alzheimer's Disease Research Center clinic appointment with a Neurologist

Services offered by the UCLA - Easton Center include:

  • Neuropsychological testing
  • Initial evaluations
  • Second opinions
  • Follow-up medical care after initial diagnosis
  • Research opportunities including clinical drug trials
  • Linkage to community social services

Evaluation Process:

  • The evaluation process is usually completed in two visits with scheduled diagnostic tests between the two appointments.
  • Diagnostic tests may include a neuropsychological assessment, functional brain imaging, structural brain imaging, and lab work.
  • Patients have the option of receiving ongoing clinical management of their memory loss or dementia symptoms at UCLA.
  • Educational information and referrals to appropriate community resources are provided to patients, families, and caregivers.
  • Referral of eligible patients to research programs including the Mary S. Easton Center for Alzheimer's Disease Research at UCLA, the Alzheimer's Disease Cooperative Study, as well as clinical drug trials designed to develop new therapies for memory loss, Alzheimer's disease and other dementias.

Testing of new drugs:

  • New drugs are continuously being evaluated for their usefulness in treating Alzheimer's disease. Patients are evaluated for the trials and invited to participate if appropriate.

Physicians (9)